Physician profile
Andrew Michael Bohunicky
NPI 1821633629
$523.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $481 · 2023: $42.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248.92 | 2021-2023 | |
| Abbvie INC. | $51.89 | 2021 | |
| Glaxosmithkline, LLC. | $50.51 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $33.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.61 | 2021 | |
| Daiichi Sankyo INC. | $19.70 | 2021 | |
| Lilly USA, LLC | $16.54 | 2021 | |
| Currax Pharmaceuticals LLC | $15.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.71 | 2021 | |
| Amgen INC. | $14.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.19 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bohunicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.